Respiration Scan

Company Overview

Snapshot

Founded in January 2017 by Dr. Igal Bar-Ilan and Edan Razinovsky, Respiration Scan operates with 1–10 employees. The company has raised $5.89M across 3 funding rounds from 1 investor. In November 2021, the company secured a grant from the IIA.

Business overview

Respiration Scan develops healthcare solutions for disease prediction and diagnostics, focusing on non-invasively detecting volatile organic compounds in human breath. Its technology, which utilizes cheminformatics and machine learning, is designed to continuously learn new disease states and provide doctors with tools for earlier diagnosis. The company's platform, including the ExhalePN product, operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Diagnostics Devices markets.

Strategic signal

In April 2023, Respiration Scan was highlighted for its non-invasive solution revolutionizing respiratory diagnosis, particularly starting with pneumonia in the ICU. This indicates a significant market validation for its technology, suggesting the company was poised to address critical needs in early disease detection and improve clinical outcomes within the healthcare industry.

Company Intelligence Q&A

What is Respiration Scan's primary focus?

Respiration Scan develops healthcare solutions for disease prediction and diagnostics by non-invasively detecting volatile organic compounds in human breath.

When was Respiration Scan founded and by whom?

Respiration Scan was founded in January 2017 by Dr. Igal Bar-Ilan and Edan Razinovsky.

What is the core technology behind Respiration Scan's platform?

The company's platform utilizes cheminformatics and machine learning to diagnose new disease states via a patented breath diagnostics platform.

What was the total capital raised by Respiration Scan?

Respiration Scan raised $5.89M across 3 funding rounds.